MODEL 3100 FREQUENCY OSCILLATORY VENTILATOR
ZOLL MEDICAL CORPORATION · Decision date Jul 23, 2025
What did the FDA approve?
FDA records P890057/S029 as a supplement to PMA P890057, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 23, 2025.
FDA approval order statement
for a change in the raw material base resin for the 772722-102 pressure sense line Flex, circuit 71.0 LG, used in the 3100 Series Ventilators Patient Circuit connectors.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Anesthesiology
- Decision date
- Jul 23, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P890057/S029
- Regulatory pathway
- PMA supplement
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- LSZ
- Decision code
- APPR
- Decision date
- Jul 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: VENTILATOR, HIGH FREQUENCY.
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- LSZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P890057/S029 received
Application receipt date recorded by FDA.
P890057/S029 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P890057. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LSZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LifePulse High Frequency VentilatorP850064/S056 | Bunnell, Inc. | PMA supplement | Sep 28, 2026 | FDA |
| Bunnell, Inc. | PMA supplement | May 7, 2026 | FDA | |
LifePulse High Frequency Ventilator (HFV)P850064/S055 | Bunnell, Inc. | PMA supplement | Jul 25, 2025 | FDA |
| Bunnell, Inc. | PMA approval | Jun 30, 1988 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ZOLL MEDICAL CORPORATION
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 269 Mill Rd., Chelsmford, MA, 01824
Sources and methodology
- Original FDA record: P890057/S029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


